PRISM Registry: Pseudobulbar Affect Registry Series

PRISM Registry: Pseudobulbar Affect Registry Series
This study is currently recruiting participants.
Verified May 2011 by Avanir Pharmaceuticals

First Received on June 2, 2011.  
No Changes Posted
Sponsor: Avanir Pharmaceuticals
Information provided by: Avanir Pharmaceuticals Identifier: NCT01366027

PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That’s why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated.

The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including

  • Alzheimer’s disease
  • Amyotrophic lateral sclerosis
  • Multiple sclerosis
  • Parkinson’s disease
  • Stroke
  • Traumatic brain injury

Because this is an observational registry, it doesn’t require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.

Alzheimer’s Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple Sclerosis (MS)
Parkinson’s Disease
Traumatic Brain Injury

Study Type: Observational
Official Title: PRISM Registry: Pseudobulbar Affect Registry Series

Resource links provided by NLM:

Further study details as provided by Avanir Pharmaceuticals:

Estimated Enrollment: 10000
Study Start Date: May 2011
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The population for this study will be 18 years and over


Inclusion Criteria:

  • All participants must have underlying neurologic conditions known to be risk factors of PBA: Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson’s Disease, Stroke, and Traumatic Brain Injury.
  • The population for this study will be 18 years and over
  Contacts and Locations

Please refer to this study by its identifier: NCT01366027

Contact: Randall Kaye, MD 1-855-472-2722

United States, California
Avanir Pharmaceuticals Recruiting
Aliso Viejo, California, United States, 92656
Contact: Randall Kaye, MD     855-472-2722        
Sponsors and Collaborators
Avanir Pharmaceuticals
Study Chair: Randall Kaye, MD Avanir Pharmaceuticals
  More Information

No publications provided

Responsible Party: Randall Kaye, MD, Chief Medical Officer, Avanir Pharmaceuticals Identifier: NCT01366027    
History of Changes
Other Study ID Numbers: 11-AVR-REG-001
Study First Received: June 2, 2011
Last Updated: June 2, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Avanir Pharmaceuticals:

pseudobulbar affect

Additional relevant MeSH terms:

Alzheimer Disease
Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Parkinson Disease
Motor Neuron Disease
Brain Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Spinal Cord Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders
Pathologic Processes processed this record on August 21, 2012

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




3 + twelve =